Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

被引：0
|
作者：
Dominic Pilon
Erik Muser
Patrick Lefebvre
Rhiannon Kamstra
Bruno Emond
Kruti Joshi
机构：
[1] Groupe d’analyse,
[2] Ltée,undefined
[3] Janssen Scientific Affairs,undefined
[4] LLC,undefined
来源：
BMC Psychiatry | / 17卷
关键词：
Oral Atypical Antipsychotics (OAA); Healthcare Resource Utilization; Mean Monthly Cost; Medical Cost Savings; Higher Pharmacy Costs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
    Sliwa, Jennifer Kern
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Turkoz, Ibrahim
    Alphs, Larry
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 375 - 385
  • [22] The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia
    El Khoury, Antoine C.
    Pilon, Dominic
    Morrison, Laura
    Shak, Nina
    Vermette-Laforme, Maude
    Amos, Tony B.
    Kim, Edward
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (03) : 395 - 405
  • [23] Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France
    Gozlan, G.
    Lecardeur, L.
    Monfort, A-S
    Doz, M.
    Ortiz, I
    Larroumets, P.
    Lafuma, A.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2018, 44 (06): : 496 - 503
  • [24] Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
    Xiao, Yongling
    Muser, Erik
    Fu, Dong-Jing
    Lafeuille, Marie-Helene
    Pilon, Dominic
    Emond, Bruno
    Wu, Allen
    Duh, Mei Sheng
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (04) : 759 - 769
  • [25] Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
    Pesa J.A.
    Muser E.
    Montejano L.B.
    Smith D.M.
    Meyers O.I.
    Drugs - Real World Outcomes, 2015, 2 (4) : 377 - 385
  • [26] TREATMENT PATTERNS IN MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA REACHING STABILIZED MAINTENANCE WITH ONCE-MONTHLY PALIPERIDONE PALMITATE THERAPY
    Pilon, D.
    Muser, E.
    Emond, B.
    Xiao, Y.
    Amos, T.
    Lefebvre, P.
    Benson, C.
    VALUE IN HEALTH, 2016, 19 (03) : A196 - A196
  • [27] Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
    Lafeuille M.-H.
    Tandon N.
    Tiggelaar S.
    Kamstra R.
    Lefebvre P.
    Kim E.
    Yue Y.
    Joshi K.
    Drugs - Real World Outcomes, 2018, 5 (1) : 81 - 90
  • [28] PROJECTING THE ECONOMIC OUTCOMES OF SWITCHING PATIENTS WITH SCHIZOPHRENIA FROM ORAL ATYPICAL ANTIPSYCHOTICS TO ONCE-MONTHLY PALIPERIDONE PALMITATE AND ONCE-EVERY-THREE-MONTHS PALIPERIDONE PALMITATE
    Lin, D.
    Morrison, L.
    Pilon, D.
    Benson, C.
    Ghelerter, I
    Vermette-Laforme, M.
    Lefebvre, P.
    VALUE IN HEALTH, 2021, 24 : S129 - S129
  • [29] HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH PALIPERIDONE PALMITATE VERSUS ORAL ATYPICAL ANTIPSYCHOTICS AMONG PATIENTS WITH SCHIZOAFFECTIVE DISORDER
    Pesa, J. A.
    Muser, E.
    Montejano, L. B.
    Kim, G.
    Smith, D. M.
    VALUE IN HEALTH, 2015, 18 (03) : A118 - A119
  • [30] Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis
    Pilon, Dominic
    Amos, Tony B.
    Kamstra, Rhiannon
    Manceur, Ameur M.
    El Khoury, Antoine C.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (01) : 41 - 49
12345